Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators. Saurat JH, et al. Among authors: stingl g. Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28. Br J Dermatol. 2008. PMID: 18047523 Clinical Trial.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Lebwohl M, et al. Among authors: stingl g. N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824. N Engl J Med. 2015. PMID: 26422722 Free article. Clinical Trial.
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, Ferrándiz C, Sinclair R, Saurat JH; CLEAR Multinational Study Group. Sterry W, et al. Among authors: stingl g. J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56. doi: 10.1111/j.1610-0387.2006.06111.x. J Dtsch Dermatol Ges. 2006. PMID: 17081270 Clinical Trial. English, German.
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Reich K, et al. Among authors: stingl g. Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8. Exp Dermatol. 2015. PMID: 25828362 Free PMC article. Clinical Trial.
Consensus statement on the safety profile of topical calcineurin inhibitors.
Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Paller A, de Prost Y, Puig L, Ring J, Saurat JH, Schwarz T, Shear N, Stingl G, Taieb A, Thestrup-Pedersen K; Pediatric Advisory Committee of the Food and Drug Administration. Bieber T, et al. Among authors: stingl g. Dermatology. 2005;211(2):77-8. doi: 10.1159/000086431. Dermatology. 2005. PMID: 16088148 No abstract available.
Immunosuppressive therapy in dermatology and PML.
Sterry W, Bagot M, Ferrandiz C, Kragballe K, Papp K, Stingl G. Sterry W, et al. Among authors: stingl g. J Dtsch Dermatol Ges. 2009 Jan;7(1):5. doi: 10.1111/j.1610-0387.2008.06993.x. J Dtsch Dermatol Ges. 2009. PMID: 19138293 Free PMC article. No abstract available.
Efalizumab in routine use: a clinical experience.
Selenko-Gebauer N, Karlhofer F, Stingl G. Selenko-Gebauer N, et al. Among authors: stingl g. Br J Dermatol. 2007 Apr;156 Suppl 2:1-6. doi: 10.1111/j.1365-2133.2007.07762.x. Br J Dermatol. 2007. PMID: 17371316
412 results